Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

17.32
-0.2700-1.53%
Post-market: 17.500.1800+1.04%19:48 EDT
Volume:10.81M
Turnover:188.96M
Market Cap:19.87B
PE:-15.16
High:17.79
Open:17.64
Low:17.27
Close:17.59
Loading ...

Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Business Wire
·
10 Feb

Teva Pharmaceutical Industries Files Mixed Shelf Registration

MT Newswires Live
·
08 Feb

Teva files automatic mixed securities shelf

TIPRANKS
·
08 Feb

Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
07 Feb

Saverone 2014 Wins Contract To Equip Teva Pharmaceutical's 50-Truck Fleet With Safety System

MT Newswires Live
·
04 Feb

SaverOne Expands Driver Safety System Deployment with Teva Pharmaceutical

TIPRANKS
·
04 Feb

Saverone Announces New Deployment of Its Driver Distraction Prevention System in Teva Pharmaceutical’s Truck Fleet

THOMSON REUTERS
·
04 Feb

SaverOne Announces New Deployment of Its Driver Distraction Prevention System in Teva Pharmaceutical’s Truck Fleet

GlobeNewswire
·
04 Feb

Teva Pharmaceutical (TEVA) Gets a Buy from Argus Research

TIPRANKS
·
31 Jan

Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ...

GuruFocus.com
·
31 Jan

Teva’s Earnings Call: Growth Amid Challenges

TIPRANKS
·
31 Jan

Stock Track | Teva Pharmaceutical Plummets 5% on Disappointing 2025 Earnings Guidance Despite Solid Q4 Results

Stock Track
·
31 Jan

TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates

Zacks
·
31 Jan

Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?

Insider Monkey
·
30 Jan

Teva Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
30 Jan

Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
30 Jan

Teva price target lowered to $26 from $28 at Barclays

TIPRANKS
·
30 Jan

Teva Pharmaceuticals Reports Continued Growth in 2024

TIPRANKS
·
30 Jan

Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook

Stock Track
·
30 Jan

Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
30 Jan